Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapid Infusion Rituximab in Adolescents
NCT02484053Phase 1Completed
- Sponsor
- Baylor College of Medicine
- Start
- Jun 2015
- Primary completion
- Jan 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of rituximab in hematologic disorder, cancer and rheumatism (2 arms), sponsored by Baylor College of Medicine. Primary endpoint: Safety of rapid infusion rituximab at 6 weeks. Started Jun 2015; status: completed.
02
Drugs
rituximab
03
Conditions
hematologic disordercancerrheumatism
Beyond the preview
Go deeper on NCT02484053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02484053.